Download to read offline

















The document summarizes key information about inactivated polio vaccine (IPV), including that it is made from killed poliovirus strains, it produces antibodies but not intestinal immunity, it requires multiple doses for protection, and it carries no risk of vaccine-associated paralysis unlike the live oral polio vaccine (OPV). IPV is recommended for routine use in industrialized countries where the risk of vaccine-derived polio is greater than wild poliovirus, while OPV is used to contain outbreaks and in immunization programs in developing countries.
Introduction to IPV, administration and dosage, and immunity details.
Administration routes, dosage recommendations, and efficacy of IPV, including disadvantages.
Risks associated with IPV and the use of combined IPV and OPV vaccination strategies.
Objectives of PPI, details about immunization rounds and age groups targeted.
Measures taken by the Indian government to sustain a polio-free status and the last recorded case.
















